Clinical use of biochemical markers of bone remodeling: Current status and future directions

Osteoporosis International

Volumn 11, Issue 6, 2000, Pages 467-480

  Looker, A C ^a   Bauer, D C ^b   Chesnut Iii, C H ^c   Gundberg, C M ^d   Hochberg, M C ^e   Klee, G ^f   Kleerekoper, M ^g   Watts, N B ^h   Bell, N H ⁱ  

^a NATIONAL CENTER FOR HEALTH STATISTICS   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d YALE UNIVERSITY   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^f MAYO CLINIC   (United States)

^g WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Bone turnover markers; Clinical management; Osteoporosis

Indexed keywords

BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE;

BONE DENSITY; BONE DISEASE; BONE MINERAL; BONE REMODELING; BONE TURNOVER; HORMONE SUBSTITUTION; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; REVIEW;

BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; BONE RESORPTION; FEMALE; FORECASTING; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; RESEARCH; RISK FACTORS;

EID: 0033839670     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001980070088     Document Type: Review

References (119)

1. Predicting the effect of antiresorptive treatments on risk of vertebral fractures: A meta-analysis
2. Drug therapy for vertebral fractures in osteoporosis: Evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy
3. Basic science and clinical utility of biochemical markers of bone turnover: A congress report
4. Molecular basis and clinical application of biological markers of bone turnover
5. Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study
6. Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurements for the prediction of hip fracture in elderly women? The EPIDOS prospective study
7. Serum markers of bone turnover and fractures of the hip and spine: A prospective study
8. Case-control analysis of bone resorption markers, disability, and hip fracture risk: The Rotterdam study
9. Assessment of biochemical markers of bone metabolism in relation to the occurrence of fracture: A retrospective and prospective population-based study of women
10. Skeletal alkaline phosphatase (Tandem Ostase) measurements predict vertebral fractures: A prospective study
11. Bone density at various sites for prediction of hip fracture
12. Long-term fracture prediction by bone mineral assessed at different skeletal sites
13. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group
14. Antifracture efficacy of antiresorptive treatments are associated with changes in bone density
15. Bone age, mineral density, and fatigue damage
16. Bone remodeling in hip fracture
17. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group
18. Relationship of bone turnover to bone density and fractures
19. Should BMD be measured at multiple sites to predict risk of fracture in elderly women?
20. Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine
21. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis
22. Sexual differences in bone markers and bone mineral density of normal Chinese
23. Bone mineral density and biochemical markers of bone turnover in healthy elderly men and women
24. Specific changes of urinary excretion of cross-linked N-telopeptides of type I collagen in pre- and postmenopausal women: Correlation with other markers of bone turnover
25. Serum osteocalcin and bone mineral density at various skeletal sites: A study performed with three different assays
26. Estimation of bone mineral density and bone loss by means of bone metabolic markers in postmenopausal women
27. Evaluation of bone metabolic markers as indicators of osteopenia in climacteric women
28. Age, menopause, bone turnover markers and lumbar bone loss in healthy Japanese women
29. Urinary N-telopeptide levels discriminate normal, osteopenic, and osteoporotic bone mineral density
30. Bone turnover markers and bone density across the menopausal transition
31. New biochemical markers of bone resorption derived from collagen breakdown in the study of postmenopausal osteoporosis
32. Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis
33. Radial bone mineral density in pre- and perimenopausal women: A prospective study of rates and risk factors for loss
34. The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: A 1-year randomized, double-blind, placebo controlled dose-finding study
35. Assessment of age and risk factors on bone density and bone turnover in healthy premenopausal women
36. Biochemical assessment of bone loss in patients on long-term thyroid hormone treatment
37. High bone turnover is associated with low bone mass in both pre- and postmenopausal women
38. Temporal relationship between bone loss and increased bone turnover: A longitudinal study following natural menopause
39. Hormone replacement therapy in postmenopausal women: Urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density
40. Dose-response relationships for alendronate treatment in osteoporotic elderly women
41. The effect of menopause and hormone replacement therapy on bone alkaline phosphatase
42. Applications of an enzyme immunoassay for a new marker of bone resorption (Crosslaps): Follow-up on hormone replacement therapy and osteoporosis risk assessment
43. Differential effects of dietary calcium augmentation and hormone replacement therapy on bone turnover and serum levels of calcitrophic hormones
44. Can biochemical markers predict bone loss at the hip and spine? A 4-year prospective study of 141 early postmenopausal women
45. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links
46. The response in spinal bone mass to tibolone treatment is related to bone turnover in elderly women
47. The diagnostic validity of urinary free pyridinolines to identify women at risk of osteoporosis
48. Biochemical markers of bone turnover reflect femoral bone loss in elderly women
49. Rapid bone loss is associated with increased levels of biochemical markers
50. The usefulness of bone turnover in predicting the response to transdermal estrogen therapy in postmenopausal osteoporosis
51. Monitoring estrogen replacement therapy and identifying rapid bone losers with an immunoassay for deoxypyridinoline
52. Biochemical markers predict spine but not hip BMD response to alendronate: The Fracture Intervention Trial (FIT)
53. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial
54. Biochemical markers of bone turnover and prediction of hip bone loss in older women: The Study of Osteoporotic Fractures
55. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: The OFELY study
56. Bone density change and biochemical indices of skeletal turnover
57. 3: A prospective, controlled randomized study
58. Serum N-terminal osteocalcin is a good indicator for estimating responders to hormone replacement therapy in postmenopausal women
59. A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover
60. Estrogen action on the bone mass of postmenopausal women is dependent on body mass and initial bone density
61. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis
62. High bone density in hyperandrogenic women: Effect of gonadotropin-releasing hormone agonist alone or in conjunction with estrogen-progestin replacement
63. Prevention of estrogen deficiency-related bone loss with human parathyroid hormone (1-34)
64. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: A randomized clinical trial
65. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation
66. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment
67. Biochemical markers of bone turnover to monitor the bone response to postmenopausal hormone replacement therapy
68. The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women
69. Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: Prediction of bone mass changes during treatment
70. The effect of gonadotropin-releasing hormone agonist on type I collagen C-telopeptide and N-telopeptide: The predictive value of biochemical markers of bone turnover
71. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women
72. The performance and utility of biochemical markers of bone turnover: Do we know enough to use them in clinical practice?
73. Biological variation of biochemical bone markers
74. Intra-individual variation in bone resorption markers in urine
75. Abnormalities in circadian patterns of bone resorption and renal calcium conservation in type I osteoporosis
76. The effect of calcium supplementation on the circadian rhythm of bone resorption
77. Diurnal rhythm in serum activity of wheat germ lectin-precipitable alkaline phosphatase: Temporal relationships with the diurnal rhythm of serum osteocalcin
78. Diurnal rhythm and 24-hour integrated concentrations of serum osteocalcin in normals: Influence of age, sex, season, and smoking habits
79. Seasonal variation of biochemical indexes of bone turnover: Results of a population-based study
80. Changes in biochemical markers of osteoblastic activity during the menstrual cycle
81. Estimating an individual's true cholesterol level and response to intervention
82. Intra- and inter-individual biological variability data bank
83. Biological variation in bone-derived biochemical markers in serum
84. Response of biochemical markers of bone turnover to hormone replacement therapy: Impact of biological variability
85. Intra-individual variation in serum type I procollagen carboxy-terminal propeptide and type I collagen carboxy-terminal cross-linked telopeptide concentrations
86. Intraindividual variability in bone markers in the urine
87. Physiological variations in the urinary excretion of pyridinium crosslinks of collagen
88. Inter and intra-individual variations in urinary excretion of pyridinium crosslinks of collagen in healthy young adults
89. Factors affecting the assay of urinary 3-hydroxy-pyridinium crosslinks of collagen as markers of bone resorption
90. Immunoassay for urinary pyridinoline: The new marker of bone resorption
91. Determination of the intrasubject variability in NTx excretion in postmenopausal women
92. Intra-individual variation in fasting urinary calcium- and hydroxyproline-creatinine ratios measured in metabolic bone clinic patients as both outpatients and inpatients
93. The reproducibility of bone-related biochemical variables in post-menopausal women
94. Biological variation in urinary excretion of pyridinium crosslinks: Recommendations for the optimum specimen
95. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen
96. Serum levels of pyridinium crosslinks in postmenopausal women and in Paget's disease of bone
97. Novel serum markers of bone resorption: Clinical assessment and comparison with established urinary indices
98. Clinical evaluation of the Serum Crosslaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-peptides
99. Biological variability of serum and urinary N-telopeptide of type I collagen in postmenopausal women
100. Short-term and long-term intra-individual variations and critical differences of clinical chemical laboratory parameters
101. Preventive effects of transdermal 17β-estradiol on osteoporotic changes after surgical menopause: A two-year placebo-controlled trial
102. Effect of menopause and hormone replacement therapy on urinary excretion of pyridinium cross-links: A longitudinal and cross-sectional study
103. The effect of the menopause and hormone replacement therapy on serum carboxy-terminal propeptide of type I collagen
104. Effect of the menopause and hormone replacement therapy on the carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen
105. Bone loss in elderly women prevented by ultralow doses of parenteral 17β-estradiol
106. Evaluation of a new commercial IRMA for bone-specific alkaline phosphatase during treatment with hormone replacement therapy and calcitonin
107. Effect of transdermal 17β-estradiol and oral conjugated equine estrogens on biochemical parameters of bone resorption in natural menopause
108. Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women
109. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis
110. Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling
111. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis
112. Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis
113. Effect of three years of oral alendronate treatment in postmenopausl women with osteoporosis
114. Alendronate prevents postmenopausal bone loss in women without osteoporosis
115. Blood lipid measurements: Variations and practical utility
116. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults
117. Monitoring alendronate therapy for osteoporosis
118. Prediction of rapid bone loss in postmenopausal women